Abeona Therapeutics (ABEO) Stock Price Down 7.6%
Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) dropped 7.6% during trading on Tuesday . The stock traded as low as $15.25 and last traded at $15.30. Approximately 737,100 shares changed hands during mid-day trading, an increase of 17% from the average daily volume of 628,438 shares. The stock had previously closed at $16.55.
ABEO has been the subject of several research reports. Zacks Investment Research downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. HC Wainwright restated a “buy” rating and set a $30.00 price objective (up previously from $20.00) on shares of Abeona Therapeutics in a research report on Monday, October 9th. Royal Bank Of Canada started coverage on shares of Abeona Therapeutics in a research report on Thursday, September 14th. They set an “outperform” rating and a $23.00 price objective for the company. Maxim Group set a $17.00 price objective on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, August 29th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $21.00 price objective on shares of Abeona Therapeutics in a research report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the stock. Abeona Therapeutics has an average rating of “Buy” and a consensus target price of $26.10.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.05. Abeona Therapeutics had a negative net margin of 2,946.58% and a negative return on equity of 27.69%. The business had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.22 million. research analysts expect that Abeona Therapeutics Inc will post -0.6 EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the company. State of Wisconsin Investment Board acquired a new position in shares of Abeona Therapeutics during the second quarter worth approximately $122,000. Rhumbline Advisers bought a new position in shares of Abeona Therapeutics during the second quarter worth about $190,000. Bank of New York Mellon Corp grew its holdings in shares of Abeona Therapeutics by 125.8% during the first quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 23,358 shares in the last quarter. Schwab Charles Investment Management Inc. bought a new position in shares of Abeona Therapeutics during the second quarter worth about $264,000. Finally, California State Teachers Retirement System bought a new position in shares of Abeona Therapeutics during the second quarter worth about $275,000. 41.95% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Abeona Therapeutics (ABEO) Stock Price Down 7.6%” was first posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.dailypolitical.com/2017/12/07/abeona-therapeutics-abeo-stock-price-down-7-6.html.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.